Lowering levels of tau protein improved multiple symptoms of autism spectrum disorders (ASD) in two different mouse models of the disease, both of which are driven by hyperactivity of the mTOR PI3 kinase pathway.
BioWorld looks at translational medicine, including: Finding the next pandemic threat early on; Microglial fresh start helps heal brain trauma; Finding the silent majority; Anatomy study reveals schizophrenia subtypes; Increasing immune activity improves autoimmunity; How cancer cells hibernate…; …And who makes their bed; Blocking trash trashes MSI-hi tumors; New splicing factor implicated in muscular dystrophy.
Beyond every binary is a more complex reality. And so it is with driver and passenger mutations. The separation of tumor mutations into drivers and passengers underpins much progress in the development of targeted therapies.
Keeping you up to date on recent developments in diagnostics, including: Chest CT bests assays in diagnosing Covid-19; Sweat sensor keeps tabs on stress; Oligodendrocyte-neural connections not just about myelin; Sharper look yields new potential kinase target in ovarian cancer.
Everything’s good for something. Including, it turns out, 5’ untranslated trinucleotide repeats. In the Feb. 17, 2020, issue of Nature Neuroscience, researchers have demonstrated a role for such repeats in controlling protein levels of fragile X mental retardation protein (FMRP).
Keeping you up to date on recent developments in neurology, including: Therapeutic cooling targets site of newborn brain injury; Boys with inattention-hyperactivity face increased risk for traumatic brain injuries; Nanogold improves MS symptoms; Thanks for the memories, myelin.
BioWorld looks at translational medicine, including: Noncoding RNA protects blood vessel walls; PD-1 blockade interferes with opioid analgesia; T-cell population is biomarker for beta cell function; Glutaminase 1 is NASH target; Oligodendrocyte-neural connections not just about myelin; Sharper look yields new potential kinase target in ovarian cancer; Structural insights could enable specific activation of GPCRs; Autophagy activation may prevent metastasis; AI finds structurally unique antibiotics.
Keeping you up to date on recent developments in diagnostics, including: Detailed mapping of breast tumors sheds light on role of genetic variations; Leveraging AI in breast cancer diagnosis; T cell population is biomarker for β-cell function; Oligodendrocyte-neural connections not just about myelin.
Beyond every binary is a more complex reality. And so it is with driver and passenger mutations. The separation of tumor mutations into drivers and passengers underpins much progress in the development of targeted therapies. By looking at passenger mutations more carefully, though, researchers at Yale University have shown that passenger mutations, too, played a role in how tumors progressed.
Parkinson’s disease (PD) is a neurodegenerative disorder. But not just. And it may not start that way.
There is increasing evidence that a-synuclein, the protein whose aggregates eventually destroy midbrain dopaminergic neurons in PD (and that are the cause of other diseases collectively known as the synucleinopathies), first aggregates “in enteric neurons, the neurons that control gastrointestinal function,” Collin Challis told BioWorld.
